Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Hodgkin Disease

HER2-negative Breast Cancer

Carcinoma, Renal Cell

Colonic Neoplasms

Lung Diseases, Interstitial

Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Triple Negative Breast Neoplasms

Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Turcot syndrome, Glioblastoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lung Neoplasms

Adenocarcinoma, Uterine Cervical Neoplasms

Advanced Bladder Cancer

Primary Glioblastoma

Multiple Myeloma, Triple Negative Breast Neoplasms

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Brain Neoplasms, Meningeal Carcinomatosis

Carcinoma, Renal Cell

Breast Neoplasms, Triple Negative Breast Neoplasms

Biliary Tract Neoplasms

Nasopharyngeal Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Turcot syndrome, Colonic Neoplasms, Microsatellite Instability

Thyroid Neoplasms

Head and Neck Neoplasms

Cholangiocarcinoma, Klatskin Tumor

Hodgkin Disease

Glioblastoma

Squamous Cell Carcinoma of Head and Neck

Uterine Cervical Neoplasms

Head and Neck Neoplasms

Lung Neoplasms

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

Non-small Cell Lung Cancer Metastatic

Gastroesophageal Junction Cancer

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

CUE-101with Pembrolizumab for LA-HPV+HNSCCs

Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC

ILLUMINE

NEO COMBAT XL

PLANET

ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma

Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases

PRELUDE

RESET C2

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer

BLP-HCC

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

META-1

Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

PANDA-VAC

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Chrono-EVP

MATVAC-1

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer

Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

ADAPT-TN-IV

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

LumOnate

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer

Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma

PREMICES

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma

NEODISCO

Pembro-FLASH

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

BROTHER

A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC

SPRING

Perioperative Immunotherapy for NSCLC (ECTOP-1030)

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

KEYPARTNER

Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma